Morgan Stanley Adjusts PT on Quest Diagnostics to $260 From $226, Maintains Overweight Rating
Morgan Stanley raised its price target for Quest Diagnostics to $260 from $226 and kept an Overweight rating, according to the note cited by MT Newswires. The article also mentions Evercore ISI cutting its target to $240 from $225. Quest Diagnostics last closed at $227.90.
How this was made
The 30-second read
Why it matters
For traders, the actionable element is the PT change ($260 vs $226) and maintained Overweight rating; however, the article does not provide new Quest-specific financial results, guidance, or events.
Market read
This is a valuation call update rather than a fundamental catalyst, so it may influence short-term sentiment but is unlikely to drive a major repricing alone.
What to watch
The text also notes Evercore cut its PT to $240 from $225, implying mixed sell-side positioning that could cap upside follow-through.
Background
The piece is a sell-side update summarizing Morgan Stanley’s revised price target and rating for Quest Diagnostics.
Ticker impact
Morgan Stanley raised its Quest Diagnostics price target to $260 from $226 and kept an Overweight rating, signaling revised valuation expectations.
Near-term bias modestly positive versus Street, but magnitude likely limited because it is an analyst PT change without new fundamentals disclosed here.
The article contains only the PT/rating adjustment and does not include new Quest guidance, results, or regulatory/contract events.
Market effects
Could marginally support sentiment for diagnostic testing peers via read-across to valuation/earnings visibility, but no peer-specific catalyst is described.
Primarily US large-cap healthcare/diagnostics sentiment; no regional macro linkage stated.
Limited global impact; the note is company-specific with no international policy or supply-chain event mentioned.
Counterpoint
A PT raise can reflect model/assumption changes rather than improved fundamentals, so the stock may not follow if the market already priced in similar expectations.
Key entities
- companyQuest Diagnostics Incorporated
Subject of the analyst price-target adjustment and rating maintenance.
- analyst_firmMorgan Stanley
Raised Quest Diagnostics PT to $260 from $226 and maintained Overweight.
- analyst_firmEvercore ISI
Cut Quest Diagnostics PT to $240 from $225 (mentioned as context).
